Vitiligo
☆ Germaniyaning 2022 yilgi Stiftung Warentest natijalariga ko'ra, iste'molchilarning ModelDermdan qoniqish darajasi pullik teletibbiyot maslahatlariga qaraganda bir oz pastroq bo'lgan.
Barmoqlarning vitiligosini davolash boshqa sohalarga qaraganda qiyinroq. Kosmetik jihatdan yoqimsiz bo'lishidan tashqari, vitiligo oddiy va yuqumli emas. Dermatologiyada eng samarali davolash - fototerapiya yoki lazer bilan davolash (eksimer) kamida 1 yil davomida haftasiga 2-3 marta. Agar moliyaviy sabablarga ko'ra yoki band bo'lganingiz uchun tez-tez kasalxonaga bora olmasangiz, uyda foydalanish uchun tasdiqlangan fototerapiya apparatini sinab ko'rishingiz mumkin.
Ko'z qovog'ining vitiligosi
Qo'lda Vitiligo
References
Vitiligo - bu melanotsitlarning yo'qolishi tufayli oq teri dog'larini keltirib chiqaradigan keng tarqalgan teri kasalligi. So'nggi tadqiqotlar shuni ko'rsatadiki, bu otoimmün kasallik. Bu ko'pincha kosmetik muammo sifatida qaralsa-da, bu ruhiy farovonlik va kundalik hayotga chuqur ta'sir qilishi mumkin. 2011 yilda mutaxassislar segmental vitiligo deb nomlangan turni boshqalardan alohida tasnifladilar.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Faol vitiligo bilan og'rigan bemorlarda tizimli glyukokortikoidlar, fototerapiya va tizimli immunosupressantlar kabi bir nechta davolash usullari mavjud. Barqaror vitiligo bilan og'rigan bemorlar topikal kortikosteroidlar, topikal kalsinevrin inhibitörleri, fototerapiya va transplantatsiya protseduralaridan xalos bo'lishlari mumkin. Vitiligoning asosiy jarayonlarini tushunishdagi so'nggi yutuqlar maqsadli davolash usullarini ishlab chiqishga olib keldi. Hozirgi vaqtda JAK ingibitorlari yashirin infektsiyalarni faollashtirish xavfi va boshqa immunosupressiv vositalar bilan keng tarqalgan tizimli nojo'ya ta'sirlarga qaramay, yaxshi tolerantlik va funktsional natijalarni taklif qiluvchi eng istiqbolli hisoblanadi. Davom etilayotgan tadqiqotlar vitiligo rivojlanishida ishtirok etadigan asosiy sitokinlarni aniqlashga qaratilgan (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . Ushbu sitokinlarni blokirovka qilish hayvonlar modellarida va ba'zi bemorlarda va'da berdi. Bundan tashqari, miRNA-based therapeutics va adoptive Treg cell therapy bo'yicha tergov harakatlari olib borilmoqda.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Vitiligo uchun ma'lum davo yo'q. Ochiq teriga ega bo'lganlar uchun quyoshdan himoyalovchi krem va bo'yanish odatda tavsiya etiladi. Boshqa davolash usullari steroid kremlari yoki fototerapiyani o'z ichiga olishi mumkin.
○ Davolash
#Phototherapy
#Excimer laser
#Tacrolimus ointment